期刊文献+

可手术肺腺癌主要组织相容性复合体-Ⅰ类分子链相关蛋白A和B的表达及临床意义 被引量:5

Expression of major histocompatibility complex class Ⅰ chain-related protein A and B in operable lung adenocarcinoma and its clinical significance
原文传递
导出
摘要 目的检测可手术肺腺癌组织中主要组织相容性复合体-Ⅰ类分子链相关蛋白A和B(MICA/B蛋白)的表达,探讨其临床意义。方法回顾分析郑州人民医院2002年1月至于2003年12月诊治的可手术肺腺癌100例。免疫组织化学染色法检测其MICA/B蛋白的表达,按照免疫组织化学染色评分标准≥5分者为高表达组,〈5分者为低表达组。运用χ2检验分析MICA/B蛋白与患者临床病理特征的关系。Kaplan-Meier生存曲线及Log-rank检验计算MICA/B蛋白表达与可手术肺腺癌总生存期之间的关系。采用Cox回归模型分析各个协变量单一及联合效应。结果MICA/B蛋白在可手术肺腺癌组织中的高表达率为38%(38/100)。MICA/B蛋白表达在EGFR基因突变组中的高表达率显著高于EGFR基因野生组(93.8%比11.8%,P〈0.001),而在患者不同年龄、性别、TNM分期、T分期、组织学分级及淋巴结转移之间差异均无统计学意义。MICA/B蛋白高表达组的总生存期显著短于低表达组(10.4比28.9个月,P=0.005)。结论 可手术肺腺癌组织中MICA/B蛋白高表达,与EGFR基因突变型及总生存期有密切关系,有可能是可手术肺腺癌患者预后不良的指标。 Objective To explore the expression of major histocompatibility complex class Ⅰ chainrelated protein A and B (MICA/B) in operable lung adenocarcinoma and its clinical significance. Methods Between January 2002 and December 2003, 100 patients with operable lung adenocarcinoma in People' s Hospital of Zhengzhou were collected. The expression of MICA/B was examined by immunohistochemistry staining. According to immunohistochemical staining, the cases with score ≥5 points were high expression of MICA/B while 〈 5 points were low expression of MICA/B. Chi-square test was utilized to analyze the relationship between MICA/B expression and clinieopathologic features. The association between MICA/B protein and overall survival in the patients with operable lung adenocareinoma was analyzed by Kaplan-Meier survival curve, together with Log-Rank test. The COX regression model was established to analyze the single and combined effects of these covariants. Results The percentage with high expression of MICA/B protein in operable lung adenocareinoma tissue was 38% (38/100). The over-expression rate of MICA/B protein in the group with mutant epidermal growth factor receptor (EGFR) gene was significantly higher than that in the group with wild EGFR gene (93.8% vs 11.8%, P〈0. 001 ). No statistical significance was observed between the expression of MICA/B protein and other elinieopathologic parameters, including age, sex, TNM stage, T- staging, histological grade and lymph node metastasis. Kaplan-Meier analysis showed that overexpression of MICA/B protein was closely associated with shorter survival time ( 10.4 vs 28.9 months, P = 0. 005 ). Conclusion Overexpression of MICA/B in operable lung adenocarcinoma tissue is closely related to the mutations of EGFR and overall survival, which may be a poor prognosis indicator in patients with operable lung adenocarcinoma.
出处 《中华医学杂志》 CAS CSCD 北大核心 2016年第26期2081-2085,共5页 National Medical Journal of China
基金 郑州市科技计划项目(121PLJRC532)
关键词 腺癌 细支气管肺泡 基因 MHC Ⅰ类 基因 erbB-1 预后 Adenocareinoma, bronchiolo-alveolar Genes, MHC class Ⅰ Genes, erbB-1 Prognosis
  • 相关文献

参考文献23

  • 1Lanier LL. NKG2D Receptor and Its Ligands in Host Defense [J]. Cancer Immunol Res, 2015, 3(6): 575-582. DOI: 10. 1158/2326-6066. CIR-15-0098. 被引量:1
  • 2Fang L, Gong J, Wang Y, et al. MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma [ J]. J Exp Clin Cancer Res, 2014, 33: 76. DOI: 10. 1186/s13046-014-0076-7. 被引量:1
  • 3. Watson NF, Spendlove I, Madjd Z, et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in eolorectal cancer patients[ J ]. Int J Cancer, 2006, 118(6): 1445-1452. DOI: 10. 1002/ijc. 21510. 被引量:1
  • 4Cho H, Chung JY, Kim S, et aL MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer[J]. BMC Cancer, 2014, 14: 957. DOI: 10. 1186/1471- 2407-14-957. 被引量:1
  • 5Reckamp KL. Advances in immunotherapy for non-small cell lung cancer[ J]. Clin Adv Hematol Oncol, 2015, 13 (12) : 847-853. 被引量:1
  • 6Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 1. 2015 [ J]. J Natl Compr Cane Netw, 2014, 12 (12) : 1738-1761. 被引量:1
  • 7Madjd Z, Spendlove I, Moss R, et al. Upregulation of MICA on high grade invasive operable breast carcinoma [ J ]. Cancer Immun, 2007, 7 : 17. 被引量:1
  • 8Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J]. CA Cancer J Clin, 2011, 61 (2): 69-90. DOI: 10. 3322/eaae. 20107. 被引量:1
  • 9Gabrielson E. Worldwide trends in lung cancer pathology [ J ]. Respirology, 2006, 11 (5) : 533-538. DOI: 10. 1111/j. 1440- 1843. 2006. 00909. x. 被引量:1
  • 10Sellmann L, Fenchel K, Dempke WC, et al. Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment? [J]. Transl Lung Cancer Res, 2015, 4(3) : 223-7. DOI : 10. 3978/j. issn. 2218-6751. 2015.03.01. 被引量:1

二级参考文献19

  • 1Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in China's Mainland[ J]. J Thorac Oncol, 2007, 2(5) : 430-439. 被引量:1
  • 2Shaw AT, ]reap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non small cell lung cancer who harbor EML4-ALK[J]. J Clin Oncol, 2009, 27(26) : 4247-4253. 被引量:1
  • 3Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs [ J ]. JAMA, 2014, 311(19) : 1998-2006. 被引量:1
  • 4Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy[J]. AJR Am J Roentgenol, 2010, 195 (3) : W221- W228. 被引量:1
  • 5Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpacliaxel in pulmonary adenocarcinoma [ J ]. N Engl J Med, 2009, 361 (10) : 947-957. 被引量:1
  • 6Zhou C, Wn Y, Chen G, et al. Preliminary results of randomized phase Ⅲ study comparing efficacy and safely of first-line erlotinib versus carboplatin plus gemcitabine in Chinese advanced non- small cell lung cancer patients with EGFR-activating mutation (OPTIMAL) [J]. J Clin Oncol. 2010, 28(15S) : abstract 7575. 被引量:1
  • 7Solomon B J, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer [ J ~. N Engl J Med, 2014, 371 (23): 2167-2177. 被引量:1
  • 8Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer [ J ]. Cancer Sci, 2007, 98(12) : 1817-1824. 被引量:1
  • 9Li Y, Li Y, Yang T, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer[J]. PloS One, 2013, 8(1): e52093. 被引量:1
  • 10Jin G, Jeon HS, Lee EB, et al. EML4-ALK fusion gene in Korean non-small cell lung cancer[J]. J Korean Med Sci, 2012, 27(2) : 228-230. 被引量:1

共引文献7

同被引文献24

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部